Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial-Reference-Cited by-同舟云学术

Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial

Published:2021-07-28 Issue:20 Volume:27 Page:5607-5618
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Venet David^ORCID,Rediti Mattia^ORCID,Maetens Marion,Fumagalli Debora^ORCID,Brown David N.^ORCID,Majjaj Samira,Salgado Roberto,Pusztai Lajos^ORCID,Harbeck Nadia^ORCID,El-Abed Sarra^ORCID,Wang Yingbo,Saura Cristina^ORCID,Gomez Henry^ORCID,Semiglazov Vladimir Fedorovich,de Azambuja Evandro^ORCID,Huober Jens^ORCID,Nuciforo Paolo^ORCID,Di Cosimo Serena,Piccart Martine,Loi Sherene^ORCID,Rothé Françoise,Sotiriou Christos^ORCID

Funder

Les Amis de Bordet

Breast Cancer Research Foundation

Associazione Italiana per la Ricerca sul Cancro

Fondation contre le Cancer

Fonds De La Recherche Scientifique - FNRS

National Breast Cancer Foundation

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer;JAMA Oncology;2024-05-01

2. Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials;Nature Communications;2023-11-03

3. Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level;British Journal of Cancer;2023-09-22

4. Predictive biomarkers for personalized medicine in breast cancer;Cancer Letters;2022-10

5. Neoadjuvant Trastuzumab and Pyrotinib for Locally Advanced HER2-Positive Breast Cancer (NeoATP): Primary Analysis of a Phase II Study;Clinical Cancer Research;2022-06-16